Table 2. Published report as to the efficacy of preCRT.
Study | Country | Study design/study period | No. of patients | Outcome | Complication | |
---|---|---|---|---|---|---|
preCRT | None- preCRT | |||||
Voogt (71) | Netherlands | Retrospective/2010–2018 | 132 | NA | pCR 17% R0 63% 3-y OS 68% 3-y LRFS 72% |
Major postoperative complications (Clavien-Dindo Grades III + IV + V) 31% |
Ogawa (67) | Japan | Retrospective/2000–2014 | 25a | 16a | R0 93% vs. 94% 5-y OS 46.6% vs. 29.3% (P=0.12) 5-y LRFS 24.4% vs. 0% (P=0.02) |
Major complications (Clavien-Dindo Grades III + IV), 28% vs. 43.8% (P=0.33) |
Sorrentino (72) | Italy | Retrospective/2009–2017 | 49 | 103 | R0 51% vs. 47.6% (P=0.691) 5-y DFS 60.4% vs. 33.6% (P=0.089) 5-y OS 84.6% vs. 71.1% (P=0.196) |
Postoperative complications rates, 36.7% vs. 30.1% (P=0.413) |
Bosman (63) | Netherlands | Retrospective/1994–2013 | 113b/135c | 24 | R0 62.8%/55.6% vs. 42% 5-y OS 39.1%/34.1% vs. 23% (R0 + R1 + R2) (P=0.164) 5-y LRFS 59.7%/45.9% vs. 35% (P=0.003) |
Major complications (Clavien-Dindo Grades III + IV + V), 39.7% vs. 34.8% |
PelvEx Collaborative (73) | International | Retrospective/2004–2014 | 614 | 516 | R0 59.9% vs. 56.4%5-y OS 25.6% vs. 16.4% (R0 + R1 + R2) (P=0.008) |
Major complication (Clavien-Dindo Grades III + IV) within 30 days, 61.3% vs. 38.7% (P<0.001) |
a, patients with posterior invasive LRRC; b, the full-course group did not receive radiotherapy for the primary tumor, but received a full scheme of radiotherapy for recurrence; c, the reirradiation group received radiotherapy for the primary tumor and also for local recurrence. LRRC, locally recurrent rectal cancer; preCRT, preoperative chemoradiotherapy; pCR, pathological complete response; LRFS, local relapse-free survival; OS, overall survival; NA, not available.